Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Basic Information
ID: ALA1139396
Journal: Bioorg Med Chem Lett
Title: Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors.
Authors: Wang Y, Shakespeare WC, Huang WS, Sundaramoorthi R, Lentini S, Das S, Liu S, Banda G, Wen D, Zhu X, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Dalgarno D, Clackson T, Sawyer TK.
Abstract: Novel N(9)-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N(9) on the purine core which projects hydrophobic substituents into the selectivity pocket at the rear of the ATP site. Their synthesis was achieved through a Horner-Wadsworth-Emmons reaction of N(9)-phosphorylmethylpurines and substituted benzaldehydes or Heck reactions between 9-vinyl purines and aryl halides. Most compounds are potent inhibitors of both Src and Abl kinase, and several possess good oral bioavailability.
CiteXplore: 18691885
DOI: 10.1016/j.bmcl.2008.06.042
Patent ID: ┄